PathMaker Neurosystems

PathMaker Neurosystems is a Boston-based, private, clinical-stage medical device company pioneering a novel, non-invasive neuromodulation treatment for ALS and other neurological disorders. Founded in 2014, the company is advancing its lead product, the MyoRegulator PM-2200, based on its proprietary Multi-Site DCS technology, which is designed to normalize overactive neural pathways and reduce toxic protein aggregates in motor neurons. With a veteran management team and backing from scientific pioneers, PathMaker is positioned to address a significant unmet need in neurodegenerative diseases, though it faces the inherent risks of clinical development and regulatory pathways for a new device modality.

Proprietary Multi-Site Direct Current Stimulation (Multi-Site DCS) for non-invasive neuromodulation to suppress neuronal hyperexcitability and activate protein degradation pathways.

The competitive landscape for ALS includes a few approved drugs (riluzole, edaravone, AMX0035) with modest effects and a pipeline of investigational small molecules, biologics, and gene therapies. PathMaker's non-invasive device approach is relatively unique, positioning it in a distinct niche, but it must prove superior or complementary efficacy to established and emerging pharmacologic standards of care.